J Cancer 11(2):403–413ĭ'Alessandro R, Refolo MG, Iacovazzi PA, Pesole PL, Messa C, Carr BI (2019) Ramucirumab and GSK1838705A enhance the inhibitory effects of low concentration sorafenib and regorafenib combination on HCC cell growth and motility.
Med Oncol 29(3):1817–1826Ĭhen W, Peng J, Ye J, Dai W, Li G, He Y (2020) Aberrant AFP expression characterizes a subset of hepatocellular carcinoma with distinct gene expression patterns and inferior prognosis. Clin Dev Immunol 2011:249281Ĭhen KJ, Zhou L, Xie HY, Ahmed TE, Feng XW, Zheng SS (2012) Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection. Liver Cancer 8(5):341–358īray SM, Vujanovic L, Butterfield LH (2011) Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients. Best Pract Res Clin Gastroenterol 28(5):753–770īouattour M, Mehta N, He AR, Cohen EI, Nault JC (2019) Systemic treatment for advanced hepatocellular carcinoma. Curr Mol Med 11(7):564–581īosetti C, Turati F, Vecchia La (2014) Hepatocellular carcinoma epidemiology. Sci Rep 7:12870īei R, Mizejewski GJ (2011) Alpha fetoprotein is more than a hepatocellular cancer biomarker: from spontaneous immune response in cancer patients to the development of an AFP-based cancer vaccine. Cancer Genet 216–217:37–51īai DS, Zhang C, Chen P, Jin SJ, Jiang GQ (2017) The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Agarwal R, Narayan J, Bhattacharyya A, Saraswat M, Tomar AK (2017) Gene expression profiling, pathway analysis and subtype classification reveal molecular heterogeneity in hepatocellular carcinoma and suggest subtype specific therapeutic targets.
0 kommentar(er)
